BBIBP-CorV (Sinopharm BIBP COVID-19 vaccine)

A large multi-country Phase 3 trial found that two doses of BBIBP-CorV (Sinopharm BIBP COVID-19 vaccine) given at 21-day intervals had a 79 percent efficacy against symptomatic SARS-CoV-2 infection 14 or more days following the second dose. The vaccine has a 79 percent efficacy against hospitalization.

The trial was not planned or powered to establish efficacy against severe disease in people with comorbidities, during pregnancy, or in people over the age of 60. In the trial, women were underrepresented. At the time of the evidence review, the median duration of follow-up available was 112 days.

MORE INFORMATION:

Manufacturer: Sinopharm Group
Number of Shots: 2 shots, 3 to 4 weeks apart
Type of Vaccine: Inactivated